DK3419978T3 - Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere - Google Patents

Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere Download PDF

Info

Publication number
DK3419978T3
DK3419978T3 DK17705705.6T DK17705705T DK3419978T3 DK 3419978 T3 DK3419978 T3 DK 3419978T3 DK 17705705 T DK17705705 T DK 17705705T DK 3419978 T3 DK3419978 T3 DK 3419978T3
Authority
DK
Denmark
Prior art keywords
pyrazin
pyrazolo
derivatives
jak inhibitors
jak
Prior art date
Application number
DK17705705.6T
Other languages
English (en)
Inventor
Matthew Frank Brown
Alpay DERMENCI
Andrew Fensome
Brian Stephen Gerstenberger
Matthew Merrill Hayward
Dafydd Rhys Owen
Stephen Wayne Wright
Li Huang Xing
Xiaojing Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3419978T3 publication Critical patent/DK3419978T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17705705.6T 2016-02-24 2017-02-10 Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere DK3419978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299130P 2016-02-24 2016-02-24
PCT/IB2017/050748 WO2017144995A1 (en) 2016-02-24 2017-02-10 Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Publications (1)

Publication Number Publication Date
DK3419978T3 true DK3419978T3 (da) 2020-06-02

Family

ID=58054385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17705705.6T DK3419978T3 (da) 2016-02-24 2017-02-10 Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere

Country Status (45)

Country Link
US (4) US10144738B2 (da)
EP (2) EP3712153B1 (da)
JP (1) JP6505956B2 (da)
KR (1) KR102128671B1 (da)
CN (1) CN109071546B (da)
AR (1) AR107714A1 (da)
AU (1) AU2017222417B2 (da)
CA (1) CA2958490C (da)
CL (1) CL2018002358A1 (da)
CO (1) CO2018008799A2 (da)
CR (1) CR20180372A (da)
CU (1) CU24511B1 (da)
CY (1) CY1122949T1 (da)
DK (1) DK3419978T3 (da)
DO (1) DOP2018000187A (da)
EA (1) EA035036B1 (da)
EC (1) ECSP18072109A (da)
ES (1) ES2794779T3 (da)
GE (1) GEP20217242B (da)
HK (1) HK1258157A1 (da)
HR (1) HRP20200781T1 (da)
HU (1) HUE049305T2 (da)
IL (1) IL260923B (da)
LT (1) LT3419978T (da)
MA (2) MA52987A (da)
MD (1) MD3419978T2 (da)
ME (1) ME03743B (da)
MX (1) MX2018010236A (da)
MY (1) MY189118A (da)
NI (1) NI201800080A (da)
NZ (1) NZ744349A (da)
PH (1) PH12018501788A1 (da)
PL (1) PL3419978T3 (da)
PT (1) PT3419978T (da)
RS (1) RS60261B1 (da)
RU (1) RU2718902C2 (da)
SG (1) SG11201806307YA (da)
SI (1) SI3419978T1 (da)
SV (1) SV2018005726A (da)
TN (1) TN2018000295A1 (da)
TW (1) TWI665201B (da)
UA (1) UA119835C2 (da)
UY (1) UY37133A (da)
WO (1) WO2017144995A1 (da)
ZA (1) ZA201804972B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
EA202092779A1 (ru) 2018-05-17 2021-02-02 Байер Акциенгезельшафт Замещенные дигидропиразолопиразинкарбоксамидные производные
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116592A1 (es) 2018-10-17 2021-05-26 Lilly Co Eli Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7256291B2 (ja) * 2019-04-12 2023-04-11 プライムジーン(ベイジン)カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
JP2022537877A (ja) 2019-04-30 2022-08-31 セルジーン コーポレイション アプレミラストおよびtyk2阻害剤を含む併用療法
CN114667148A (zh) * 2019-09-11 2022-06-24 辉瑞公司 用jak抑制剂治疗汗腺炎
TW202135816A (zh) * 2019-12-18 2021-10-01 美商輝瑞股份有限公司 以激酶抑制劑治療潰瘍性結腸炎
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
US20230159539A1 (en) * 2020-04-08 2023-05-25 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
JP2023542298A (ja) * 2020-09-11 2023-10-06 プルモシム セラピューティクス リミテッド ライアビリティ カンパニー 肺高血圧症を治療又は予防する組成物及び方法
CN112592345B (zh) * 2020-12-07 2024-09-13 嘉兴特科罗生物科技有限公司 一种三氮唑并吡嗪类化合物及其用途
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
WO2022208315A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Methods for treatment of vitiligo
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
TWI839945B (zh) * 2021-11-12 2024-04-21 大陸商南京明德新藥研發有限公司 吡唑並環化合物及其應用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS54560B1 (en) 2008-06-10 2016-06-30 Abbvie Inc. TRICYCLIC UNITS
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AU2011240808B2 (en) * 2010-04-14 2015-01-22 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104169284B (zh) 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
TW201605811A (zh) 2013-12-11 2016-02-16 阿爾米雷爾有限公司 作為jak抑制劑之吡唑并嘧啶-2基衍生物
EP3137454A1 (en) * 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2016009028A1 (fr) 2014-07-17 2016-01-21 Valeo Systèmes d'Essuyage Balai plat caréné d'essuie-glace
PT3227297T (pt) * 2014-12-05 2021-04-09 Array Biopharma Inc Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus
TW201639845A (zh) 2015-01-29 2016-11-16 和記黃埔醫藥(上海)有限公司 新的雜芳基和雜環化合物、其組成物及方法
CN107801397B (zh) 2015-02-13 2021-07-30 达纳-法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES

Also Published As

Publication number Publication date
HK1258157A1 (zh) 2019-11-08
MA43668B1 (fr) 2020-05-29
EP3712153A1 (en) 2020-09-23
US20190071448A1 (en) 2019-03-07
HRP20200781T1 (hr) 2020-07-24
CO2018008799A2 (es) 2018-09-20
PT3419978T (pt) 2020-06-01
TN2018000295A1 (en) 2020-01-16
TW201741313A (zh) 2017-12-01
US20230045252A1 (en) 2023-02-09
UY37133A (es) 2017-09-29
UA119835C2 (uk) 2019-08-12
ES2794779T3 (es) 2020-11-19
US10822341B2 (en) 2020-11-03
NZ744349A (en) 2023-06-30
EP3419978B1 (en) 2020-04-15
GEP20217242B (en) 2021-04-12
RU2718902C2 (ru) 2020-04-15
PL3419978T3 (pl) 2020-11-30
EP3419978A1 (en) 2019-01-02
TWI665201B (zh) 2019-07-11
MX2018010236A (es) 2019-01-14
LT3419978T (lt) 2020-06-10
CU24511B1 (es) 2021-05-12
US20200399281A1 (en) 2020-12-24
SG11201806307YA (en) 2018-09-27
HUE049305T2 (hu) 2020-09-28
SV2018005726A (es) 2018-10-24
KR20180103158A (ko) 2018-09-18
ECSP18072109A (es) 2018-10-31
EP3712153B1 (en) 2021-12-01
CA2958490C (en) 2024-02-27
JP6505956B2 (ja) 2019-04-24
KR102128671B1 (ko) 2020-06-30
CY1122949T1 (el) 2021-10-29
RS60261B1 (sr) 2020-06-30
IL260923B (en) 2022-01-01
WO2017144995A1 (en) 2017-08-31
CN109071546A (zh) 2018-12-21
ME03743B (me) 2021-04-20
NI201800080A (es) 2018-11-22
AR107714A1 (es) 2018-05-23
SI3419978T1 (sl) 2020-08-31
DOP2018000187A (es) 2019-01-31
CA2958490A1 (en) 2017-08-24
MA52987A (fr) 2021-04-28
JP2019510003A (ja) 2019-04-11
AU2017222417B2 (en) 2020-07-09
PH12018501788A1 (en) 2019-06-17
AU2017222417A1 (en) 2018-08-02
RU2018130547A (ru) 2020-03-25
MD3419978T2 (ro) 2020-07-31
EA201891463A1 (ru) 2019-03-29
US10144738B2 (en) 2018-12-04
CN109071546B (zh) 2021-03-02
EA035036B1 (ru) 2020-04-20
RU2018130547A3 (da) 2020-03-25
CR20180372A (es) 2018-09-19
BR112018015501A2 (pt) 2018-12-18
US20170240552A1 (en) 2017-08-24
MY189118A (en) 2022-01-26
CL2018002358A1 (es) 2018-11-30
CU20180078A7 (es) 2019-02-04
US11472809B2 (en) 2022-10-18
ZA201804972B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
IL261231B (en) Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors
DK3227297T3 (da) 4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
IL247948B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
HK1254651A1 (zh) 吡唑並[1,5-a]嘧啶-3-甲酰胺的環醚衍生物
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่